FDA-Cleared Apps, Explained: The 2026 Field Guide
What fda-cleared apps covers, why it matters in 2026, and the numbers decision-makers should know.
Budget season has a way of clarifying priorities, and this year the spotlight is on fda-cleared apps. Clearances and the growing catalog of regulated health software. This explainer sets out what the category actually covers, why it has moved to the center of digital therapeutics strategy, and the numbers every decision-maker should have at hand.
What it covers
Clearances and the growing catalog of regulated health software. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Digital Therapeutics coverage, and its daily developments stream into the live FDA-Cleared Apps feed.
Why it matters in 2026
Consider the current numbers: a Canadian randomized trial showed digital CBT-I built for adults 65+ meaningfully cut insomnia and anxiety (our coverage).
Meanwhile, there are 192 FDA-cleared digital therapeutics devices, but only seven are currently eligible for Medicare DMHT payment.
Meanwhile, medicare DMHT patient billing grew from 99 patients in Q1 2025 to 446 by Q3 (our coverage).
What to watch next
Three signals will tell you where fda-cleared apps goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
For leaders building 2027 plans, this belongs on the shortlist of capabilities to own rather than outsource. For the latest developments, follow our continuously updated FDA-Cleared Apps topic page.